Catalog No.
PHJ76201
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human EGFL7 (Tyr24-Ser273).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
NOTCH4-like protein,Zneu1,Multiple EGF-like domains protein 7,Epidermal growth factor-like protein 7,MEGF7,EGFL7,VE-statin,EGF-like protein 7,Multiple epidermal growth factor-like domains protein 7,Vascular endothelial statin
Purification
Purified by antigen affinity column.
Accession
Q9UHF1
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models., PMID:32191808
EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia., PMID:31672772
Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy., PMID:31298142
EGFL7 - a potential therapeutic target for multiple sclerosis?, PMID:30312112
EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors., PMID:30065025
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study., PMID:29636300
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer., PMID:29438092
Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab., PMID:28539619
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia., PMID:28533390
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer., PMID:28275117
Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection., PMID:27535973
MAGP2 controls Notch via interactions with RGD binding integrins: Identification of a novel ECM-integrin-Notch signaling axis., PMID:26808411
Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma., PMID:26328008
Notching on Cancer's Door: Notch Signaling in Brain Tumors., PMID:25601901
Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer., PMID:25140000
Real-time immuno-polymerase chain reaction in a 384-well format: detection of vascular endothelial growth factor and epidermal growth factor-like domain 7., PMID:25013989
Egfl7 is differentially expressed in arteries and veins during retinal vascular development., PMID:24595089
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy., PMID:23945239
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial., PMID:23922111
CASZ1 promotes vascular assembly and morphogenesis through the direct regulation of an EGFL7/RhoA-mediated pathway., PMID:23639441
Human anti-EGFL7 recombinant full-length antibodies selected from a mammalian cell-based antibody display library., PMID:22297616
Notch: Implications of endogenous inhibitors for therapy., PMID:20486134
For research use only. Not for human or drug use.
